Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024;97(6):546-554.
doi: 10.1159/000543266. Epub 2024 Dec 19.

International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets

Martin de Bock  1   2 , Juliana Chizo Agwu  3 , Matt Deabreu  4 , Klemen Dovc  5 , David M Maahs  6 , M Loredana Marcovecchio  7 , Farid H Mahmud  8 , Yeray Nóvoa-Medina  9 , Leena Priyambada  10 , Carmel E Smart  11   12 , Linda A DiMeglio  13
Affiliations
Practice Guideline

International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets

Martin de Bock et al. Horm Res Paediatr. 2024.

Abstract

The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and updates recommendations on the glycemic targets for children and adolescents living with diabetes. A new target for hemoglobin A1c (HbA1c) of ≤6.5% (48 mmol/mol) is recommended for those who have access to advanced diabetes technologies like continuous glucose monitoring and automated insulin delivery. This target should be encouraged for all children and adolescents living with diabetes when safely achievable. In other settings, the HbA1c target is ≤7.0% (53 mmol/mol). The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and updates recommendations on the glycemic targets for children and adolescents living with diabetes. A new target for hemoglobin A1c (HbA1c) of ≤6.5% (48 mmol/mol) is recommended for those who have access to advanced diabetes technologies like continuous glucose monitoring and automated insulin delivery. This target should be encouraged for all children and adolescents living with diabetes when safely achievable. In other settings, the HbA1c target is ≤7.0% (53 mmol/mol).

Keywords: Burden; Diabetes-related complications; Glycemic targets; Technology.

PubMed Disclaimer

Conflict of interest statement

M.B. received research funding from Novo Nordisk, Medtronic, Ypsomed, Dexcom, and Insulet; honoraria, travel expenses, or speaking fees from Novo Nordisk, Sanofi, Pfizer, Medtronic, Boehringer Ingelheim, Ypsomed, Dexcom, and Insulet; and advisory boards for Tandem and Dexcom, Nascence technology, and Tautoko Biomedical. K.D. received honoraria for participation in the speaker’s bureau of Abbott, Eli Lilly, Medtronic, Novo Nordisk A/S, and Pfizer and advisory board for Medtronic and Novo Nordisk. D.M.M. received research support from the NIH, JDRF, NSF, and the Helmsley Charitable Trust, and his institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem, and Roche. D.M.M. has consulted for Abbott, Aditxt, the Helmsley Charitable Trust, Lifescan, Mannkind, Sanofi, Novo Nordisk, Eli Lilly, Medtronic, Insulet, Dompe, BioSpex, Provention Bio, Kriya, Enable Biosciences, and Bayer. F.H.M. received research support from the Canadian Institute for Health Research (CIHR), Physicians Services Incorporated, Heart and Stroke Foundation, Diabetes UK, and Breakthrough Diabetes (formerly JDRF). C.E.S. received speaker honoraria from Medtronic and Eli Lilly and advisory boards for Abbott. M.L.M. received research support from the NIH, JDRF, and the Helmsley Charitable Trust. Her institution has received research support from Dompe, Lilly, Mannkind, Medtronic, Provention Bio, Sanofi, and Zealand. L.A.D. has consulted for Abata, Tandem, Biomea Fusion, and Vertex. She also received payment from Sanofi for a CME talk (content independently developed by her). J.C.A., M.D., Y.N.-M., and L.P. have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Summary of glycemic metrics. *For those who do not have access to advanced technologies or unable to safely attain the lower target. ‡And/or where the pursuit of the lower target does not add burden such that quality of life is impacted. DCCT, diabetes control and complications trial; TITR, time in tight range.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV, et al. . Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139(6):804–12. - PubMed
    1. Diabetes Control and Complications Trial Research Group . Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994;125(2):177–88. - PubMed
    1. Arnqvist HJ, Ludvigsson J, Nordwall M. Early increase in HbA1c trajectory predicts development of severe microangiopathy in patients with type 1 diabetes: the VISS study. BMJ Open Diabetes Res Care. 2024;12(3):e003917. - PMC - PubMed
    1. Arnqvist HJ, Westerlund MC, Fredrikson M, Ludvigsson J, Nordwall M. Impact of HbA1c followed 32 years from diagnosis of type 1 diabetes on development of severe retinopathy and nephropathy: the VISS study. Diabetes Care. 2022;45(11):2675–82. - PubMed
    1. Tienhaara E, Falck AAK, Pokka TML, Tossavainen PH. The natural history of emerging diabetic retinopathy and microalbuminuria from prepuberty to early adulthood in type 1 diabetes: a 19-year prospective clinical follow-up study. Diabet Med. 2022;39(1):e14732. - PubMed

Publication types